HANSEN GWENN (Chief Scientific Officer) sold 3.6% of their position (4.36K shares) of NURIX THERAPEUTICS, INC. on the open market
Open‑market sale worth $108.9K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 8/5/2026ACC: 0001817160-26-000017
Officer· Chief Scientific Officer
Since Jul 2020
-4.36K
Net shares
Net seller
$108.9K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
4.36K acquired · 8.71K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+4.36K
Price / share
$1.86
Trade value
$8.10K
% of position
3.7%
8/5/2026
117.23K→121.58K
Common Stock
Direct
Shares
−4.36K
Price / share
$25.00
Trade value
$108.90K
% of position
3.6%
8/5/2026
121.58K→117.23K
Total
Net shares
+0.00
Net value
-$100.80K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/5/2026 | M · Option Exercise | +4.36K | $1.86 | $8.10K | 3.7% | 117.23K | 121.58K |
| Common Stock Direct | 8/5/2026 | S · Sale | −4.36K | $25.00 | $108.90K | 3.6% | 121.58K | 117.23K |
| Total | +0.00 | -$100.80K | ||||||
Derivative Transactions1
Employee Stock Option (right to buy)
Direct
Converts to
Common Stock
4.36K shares
Shares
−4.36K
Strike price
1.86
Held after
62.31K
Exercisable
—
8/5/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) Direct | Common Stock4.36K shares | 8/5/2026 | M · Option Exercise | −4.36K | 1.86 | — | 62.31K |